SCHEMBL3815228

SCHEMBL3815228

CN(Cc1ccc(C(=O)N2CC3CCC(CC3)C2)cc1)C(=O)c1cccc(C#N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 3/20 0.42
GRM5 P41594 1/20 0.41
ATM Q13315 1/20 0.40
ACACB O00763 1/20 0.40
LMNA P02545 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HPGD P15428 2/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
SLC9A1 P19634 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3813361 0.85 NSD2 (0.49) NSD2KMT2AMEN1ALDH1A1ACACB
SCHEMBL3810933 0.84 KMT2A (0.48) KMT2AMEN1ALDH1A1LMNAHPGD
SCHEMBL3818382 0.84 HDAC1 (0.55) KMT2AMEN1ALDH1A1LMNAHDAC1
SCHEMBL4608516 0.83 NSD2 (0.41) NSD2KMT2AALDH1A1HPGDTSHR
SCHEMBL3814572 0.82 NSD2 (0.42) NSD2KMT2AMEN1ATMACACB
SCHEMBL13838903 0.82 JAK2 (0.41) NSD2KMT2AMEN1ALDH1A1ATM
SCHEMBL3815269 0.81 NSD2 (0.45) NSD2KMT2AMEN1ATMACACB
SCHEMBL3815532 0.81 NSD2 (0.47) NSD2KMT2AMEN1ALDH1A1ATM
SCHEMBL13839364 0.80 NSD2 (0.46) NSD2KMT2AMEN1ALDH1A1ATM
SCHEMBL3811232 0.80 CNR2 (0.45) NSD2KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US claimed
EP-1948190-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2008-07-30 EP claimed
WO-2007051810-A2 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES TRANSTECH PHARMA (US) 2007-05-10 WO claimed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HIGH POINT PHARMACEUTICALS, LLC 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124598-A1 PHARMACEUTICAL USE OF SUBSTITUTED AMIDES HSD11B1, HSD11B2, HSD3B1 NSD2 630/4885KMT2A 2957/4885MEN1 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.